Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cue Biopharma, Inc. (CUE : NSDQ)
 
 • Company Description   
Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

Number of Employees: 59

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.30 Daily Weekly Monthly
20 Day Moving Average: 389,674 shares
Shares Outstanding: 35.37 (millions)
Market Capitalization: $116.73 (millions)
Beta: 1.62
52 Week High: $18.42
52 Week Low: $3.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.34% -18.25%
12 Week -44.91% -38.08%
Year To Date -70.82% -64.35%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
40 GUEST STREET
-
BOSTON,MA 02135
USA
ph: 617-949-2680
fax: -
ir@cuebio.com http://www.cuebiopharma.com
 
 • General Corporate Information   
Officers
Daniel R. Passeri - Chief Executive Officer and Director
Kerri-Ann Millar - Chief Financial Officer
Aaron Fletcher - Director
Cameron Gray - Director
Peter A. Kiener - Director

Peer Information
Cue Biopharma, Inc. (CORR.)
Cue Biopharma, Inc. (RSPI)
Cue Biopharma, Inc. (CGXP)
Cue Biopharma, Inc. (BGEN)
Cue Biopharma, Inc. (GTBP)
Cue Biopharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 22978P106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 35.37
Most Recent Split Date: (:1)
Beta: 1.62
Market Capitalization: $116.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.41 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.68
Price/Cash Flow: -
Price / Sales: 8.11
EPS Growth
vs. Year Ago Period: -7.32%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -35.61%
vs. Previous Quarter: -87.88%
ROE
03/31/22 - -68.89
12/31/21 - -65.04
09/30/21 - -65.79
ROA
03/31/22 - -53.60
12/31/21 - -51.85
09/30/21 - -52.56
Current Ratio
03/31/22 - 6.66
12/31/21 - 5.35
09/30/21 - 4.58
Quick Ratio
03/31/22 - 6.66
12/31/21 - 5.35
09/30/21 - 4.58
Operating Margin
03/31/22 - -319.09
12/31/21 - -295.57
09/30/21 - -654.55
Net Margin
03/31/22 - -319.09
12/31/21 - -295.57
09/30/21 - -654.55
Pre-Tax Margin
03/31/22 - -315.65
12/31/21 - -292.26
09/30/21 - -651.69
Book Value
03/31/22 - 1.96
12/31/21 - 2.06
09/30/21 - 2.02
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.15
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 13.23
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©